SCHEMBL17350001

SCHEMBL17350001

CC(C)(C)C(=O)OCOC(=O)c1cccc2c1OB(O)[C@@H](NC(=O)c1cccs1)C2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.37
▸ HSD17B10 Q99714 2/20 0.34
▸ PRKCB P05771 1/20 0.34
▸ PRKCA P17252 1/20 0.34
▸ PRKCH P24723 1/20 0.34
▸ PRKCE Q02156 1/20 0.34
▸ PRKCD Q05655 1/20 0.34
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ HPGD P15428 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17349858 0.89 ALDH1A1 (0.36) MEN1KMT2AHPGDRAB9AALDH1A1
SCHEMBL17350005 0.88 TSHR (0.49) TSHRHSD17B10MEN1KMT2AHPGD
SCHEMBL17349760 0.88 RAB9A (0.37) TSHRHSD17B10MEN1KMT2AHPGD
SCHEMBL17349901 0.86 PRKCB (0.36) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349989 0.86 PRKCB (0.40) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17337512 0.85 PRKCB (0.35) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17337516 0.85 PRKCB (0.35) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349765 0.85 PRKCB (0.40) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349894 0.85 ADRB2 (0.35) TSHRPRKCBPRKCAPRKCHPRKCE
SCHEMBL17349773 0.85 PRKCB (0.34) PRKCBPRKCAPRKCHPRKCEPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150361107-A1 ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361107-A1 ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS SI, ALPI, GAA TSHR 4621/4885HSD17B10 769/4885PRKCB 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback